The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


The Journal of Immunology, 2007, 178, 6596 -6603
Copyright © 2007 by The American Association of Immunologists, Inc.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Forthal, D. N.
Right arrow Articles by Phan, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Forthal, D. N.
Right arrow Articles by Phan, T.

Recombinant gp120 Vaccine-Induced Antibodies Inhibit Clinical Strains of HIV-1 in the Presence of Fc Receptor-Bearing Effector Cells and Correlate Inversely with HIV Infection Rate1

Donald N. Forthal2,*, Peter B. Gilbert{dagger}, Gary Landucci* and Tran Phan*

* Division of Infectious Diseases, Department of Medicine, University of California, Irvine, CA 92697; and {dagger} Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA 98109

Nonneutralizing Abs may play a role in protecting animals and humans from lentiviral infections. We explored the Ab-dependent, cell-mediated virus inhibition (ADCVI) Ab response to recombinant gp120 (rgp120) vaccination in sera from 530 participants in the Vax 004 trial. Serum ADCVI activity was measured against a clinical R5 strain of HIV-1 using peripheral blood mononuclear effector cells from healthy donors. The level of vaccine-induced ADCVI activity correlated inversely with the rate of acquiring HIV infection following vaccination, such that for every 10% increase in ADCVI activity, there was a 6.3% decrease in the hazard rate of infection (p = 0.019). Some vaccinated individuals also mounted an ADCVI response against two other clinical R5 strains of HIV-1. However, ADCVI activity correlated poorly with neutralizing or CD4-gp120-blocking Ab activity measured against laboratory strains. Finally, the degree to which the ADCVI Ab response predicted the rate of infection was influenced by polymorphisms at the Fc{gamma}RIIa and Fc{gamma}RIIIa gene loci. These data indicate that rgp120 vaccination can elicit Abs with antiviral activity against clinical strains of HIV-1. However, such activity requires the presence of FcR-bearing effector cells. Our results provide further evidence that ADCVI may play a role in preventing HIV infection.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by the U.S. Public Health Service Grants AI52039 and 1 U01 AI068635 and the Universitywide AIDS Research Program Grant ID06-I-226.

2 Address correspondence and reprint requests to Dr. Donald N. Forthal, 3044 Hewitt Hall, University of California, Irvine, CA 92697. E-mail address: dnfortha{at}uci.edu

3 Abbreviations used in this paper: ADCVI, Ab-dependent cell-mediated virus inhibition; ADCC, Ab-dependent cellular cytotoxicity; CI, confidence interval.




This article has been cited by other articles:


Home page
NEJMHome page
S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, N. Premsri, C. Namwat, M. de Souza, E. Adams, et al.
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
N. Engl. J. Med., November 19, 2009; (2009) NEJMoa0908492v4.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
L. G. Perez, M. R. Costa, C. A. Todd, B. F. Haynes, and D. C. Montefiori
Utilization of Immunoglobulin G Fc Receptors by Human Immunodeficiency Virus Type 1: a Specific Role for Antibodies against the Membrane-Proximal External Region of gp41
J. Virol., August 1, 2009; 83(15): 7397 - 7410.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
I. Ourmanov, T. Kuwata, R. Goeken, S. Goldstein, R. Iyengar, A. Buckler-White, B. Lafont, and V. M. Hirsch
Improved Survival in Rhesus Macaques Immunized with Modified Vaccinia Virus Ankara Recombinants Expressing Simian Immunodeficiency Virus Envelope Correlates with Reduction in Memory CD4+ T-Cell Loss and Higher Titers of Neutralizing Antibody
J. Virol., June 1, 2009; 83(11): 5388 - 5400.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. H. Florese, T. Demberg, P. Xiao, L. Kuller, K. Larsen, L. E. Summers, D. Venzon, A. Cafaro, B. Ensoli, and M. Robert-Guroff
Contribution of Nonneutralizing Vaccine-Elicited Antibody Activities to Improved Protective Efficacy in Rhesus Macaques Immunized with Tat/Env Compared with Multigenic Vaccines
J. Immunol., March 15, 2009; 182(6): 3718 - 3727.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. W. Chung, E. Rollman, R. J. Center, S. J. Kent, and I. Stratov
Rapid Degranulation of NK Cells following Activation by HIV-Specific Antibodies
J. Immunol., January 15, 2009; 182(2): 1202 - 1210.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
M. Duval, M. R. Posner, and L. A. Cavacini
A Bispecific Antibody Composed of a Nonneutralizing Antibody to the gp41 Immunodominant Region and an Anti-CD89 Antibody Directs Broad Human Immunodeficiency Virus Destruction by Neutrophils
J. Virol., May 1, 2008; 82(9): 4671 - 4674.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2007 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2007 by The American Association of Immunologists, Inc. All rights reserved.